GlassScriptPhysician profile
Lisa Pizzini
NPI 1366534422
$5,370.43
in general payments reported to CMS, 2019-2025
25 companies · $908 in 2025
The $908 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,345 · 2022: $696 · 2023: $1,505 · 2024: $917 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,218 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,218.02 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $1,221.93 | 2021-2025 | Equetro, Raldesy |
| Otsuka America Pharmaceutical, INC. | $510.41 | 2021-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Teva Pharmaceuticals USA, INC. | $431.39 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $417.13 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $374.50 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $358.70 | 2022-2025 | Azstarys |
| Lundbeck LLC | $298.47 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $294.62 | 2022-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.94 | 2021-2025 | Caplyta |
| Alkermes, INC. | $226.04 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $223.88 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $177.33 | 2021-2022 | |
| Axsome Therapeutics, INC. | $176.57 | 2025 | Auvelity, Sunosi |
| Idorsia Pharmaceuticals US INC | $88.34 | 2022-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $79.04 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $50.89 | 2022-2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $39.18 | 2021 | |
| Harmony Biosciences LLC | $36.88 | 2022 | |
| Supernus Pharmaceuticals, INC. | $28.27 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $21.38 | 2025 | Xelstrym |
| Neuronetics, INC. | $19.91 | 2023 | Neurostar Tms Therapy System |
| Adlon Therapeutics L.P. | $19.58 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.81 | 2023 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $17.42 | 2023 | Subvenite, Lamotrigine |
| Lilly USA, LLC | $13.82 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Pizzini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.